PTPN6
PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.
Overview
Tyrosine phosphatase enzyme that plays important roles in controlling immune signalling pathways and fundamental physiological processes such as haematopoiesis. Dephosphorylates and negatively regulate several receptor tyrosine kinases (RTKs) such as EGFR, PDGFR and FGFR, thereby modulating their signalling activities. When recruited to immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors such as immunoglobulin-like transcript 2/LILRB1, programmed cell death protein 1/PDCD1, CD3D, CD22, CLEC12A and other receptors involved in immune regulation, initiates their dephosphorylation and subsequently inhibits downstream signalling events.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Melanoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.
- 1 · What it is
PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.
- 2 · What goes wrong in cancer
Tyrosine phosphatase enzyme that plays important roles in controlling immune signalling pathways and fundamental physiological processes such as haematopoiesis.
- 3 · How drugs use it
No product in this corpus aims at PTPN6 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9658 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P29350 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPN6 (1 evidence items, 0 assertions, 1 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0)); IntOGen PTPN6 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Tyrosine phosphatase enzyme that plays important roles in controlling immune signalling pathways and fundamental physiological processes such as haematopoiesis. Dephosphorylates and negatively regulate several receptor tyrosine kinases (RTKs) such as EGFR, PDGFR and FGFR, thereby modulating their signalling activities. When recruited to immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors such as immunoglobulin-like transcript 2/LILRB1, programmed cell death protein 1/PDCD1, CD3D, CD22, CLEC12A and other receptors involved in immune regulation, initiates their dephosphorylation and subsequently inhibits downstream signalling events. Modulates the signalling of several cytokine receptors including IL-4 receptor. Additionally, targets multiple cytoplasmic signalling molecules including STING1, LCK or STAT1 among others involved in diverse cellular processes including modulation of T-cell activation or cGAS-STING signalling. Within the nucleus, negatively regulates the activity of some transcription factors such as NFAT5 via direct dephosphorylation. Location: Cytoplasm; Nucleus (UniProt). Locus 12p13.31 (HGNC).
- Hepatocellular carcinoma: CIViC evidence names this disease
- Diffuse large B-cell lymphoma: IntOGen driver in 2 cohorts (DLBCLNOS)
- Melanoma: IntOGen driver in 1 cohort (MEL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PTPN6" OR ABSTRACT:"PTPN6" OR TITLE:"protein tyrosine phosphatase non-receptor type 6" OR ABSTRACT:"protein tyrosine phosphatase non-receptor type 6" OR TITLE:"Tyrosine-protein phosphatase non-receptor type 6" OR ABSTRACT:"Tyrosine-protein phosphatase non-receptor type 6" OR TITLE:"PTP-1C" OR ABSTRACT:"PTP-1C" OR TITLE:"SHP-1" OR ABSTRACT:"SHP-1" OR TITLE:"SHP1" OR ABSTRACT:"SHP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPN6, not a curated reading list.